✓
Open
25 Aug 2022
✓
Close
30 Aug 2022
3
Allotment
—
✓
Listing
Thu, Sep 8, 2022
Price Band
₹61 per share
Issue Size
29,78,000 shares (agg. up to ₹18 Cr)
Lot Size
2,000 Shares
Listing Date
Thu, Sep 8, 2022
Latest GMP
₹0
Est. Gain
6.97%
✦ AI Insight
GMP Trend
31-08-2022₹0Est. ₹61+6.97%
29-08-2022₹0Est. ₹61+9.84%
26-08-2022₹0Est. ₹61+9.84%
Live Subscription
| Category | Subscription (times) |
|---|---|
| Total | 6.28x |
Restated Financials (₹ Cr.)
| Period Ended | 28 Feb 2022 | 31 Mar 2021 | 31 Mar 2020 | 31 Aug 2019 |
|---|---|---|---|---|
| Assets | 36.63 | 29.01 | 24.33 | 16.15 |
| Total Income | 25.63 | 32.87 | 30.20 | 31.78 |
| Profit After Tax | 2.53 | 0.54 | 0.36 | 0.30 |
| NET Worth | 10.97 | 6.87 | 5.38 | 5.01 |
| Reserves and Surplus | 2.94 | 6.38 | 4.95 | 4.59 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Dipna Pharmachem Ltd. | SME | ₹15.21 Cr | ₹38 | 39 | ₹33.40 | -12.11% | ₹5.35 (-0.93%) |
| Jeena Sikho Lifecare Ltd. | SME | ₹55.50 Cr | ₹150 | 16.67 | ₹173.35 | +15.57% | ₹565.65 (-2.15%) |
| Achyut Healthcare Ltd. | SME | ₹3.60 Cr | ₹20 | 54.05 | ₹21.15 | +5.75% | ₹6.77 (-4.92%) |
| Fabino Life Sciences Ltd. | SME | ₹3.24 Cr | ₹36 | 133 | ₹40.35 | +12.08% | ₹20.31 (+4.96%) |
| Supriya Lifescience Ltd. | Mainboard | ₹700.00 Cr | ₹274 | null | ₹390.85 | +42.65% | ₹828.70 (-2.71%) |
| Sigachi Industries Ltd. | Mainboard | ₹125.43 Cr | ₹163 | null | ₹598.50 | +267.18% | ₹25.02 (+1.96%) |
| Ami Organics Ltd. | Mainboard | ₹569.64 Cr | ₹610 | null | ₹935.00 | +53.28% | ₹3,619.40 (+0.91%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Repayment of secured and unsecured loans | 7.50 |
| 2 | Funding the working capital requirements of the company | 6.00 |
| 3 | General Corporate Purposes | 4.27 |
About JFL Life Sciences IPO
Incorporated in 2010, JFL Life Sciences Limited is engaged in the business of manufacturing of pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets & Capsules (B-Lactam) solid oral dosage form and Tablet and capsules (general) Solid Oral Dosage Form and Oral rehydration solutions (ORS). The company's sales strategy is to sell the products in bulk to pharmaceutical marketers and traders who in turn provide the channel for sales to customers. JFL Life Sciences Limited has a market presence in PAN India and JFL's products are supplied to 10 developed and developing countries throughout the World. JFL Life Sciences Limited exports products to African, Middle Eastern, and CIS countries, mainly through merchant exporters. The company is registered with the MOH of Kenya, Nigeria, Yemen, Cambodia & Myanmar for manufacturing a particular product. Few of our products are also registered with Ukraine, Uzbekistan, and Kazakhstan (CIS countries) through merchants. JFL has two manufacturing units (on lease) in Gujarat. Competitive Strength : Product registration Experienced management and dedicated employee base Quality assurance Quality
Contact Details
JFL Life Sciences Ltd. Address309, Satyam MallOpp.Saman Complex, Nr.Vishweshwar Mahadev MandirSetteliteAhmedabad, Gujarat, 380015937729 5575cs@jfllifesciences.comVisit Website